Intravenous injection of a foamy virus vector to correct canine SCID-X1

Blood

Volumn 123, Issue 23, 2014, Pages 3578-3584

  Burtner, Christopher R ^a   Beard, Brian C ^a,b   Kennedy, Douglas R ^c   Wohlfahrt, Martin E ^a   Adair, Jennifer E ^a,b   Trobridge, Grant D ^d   Scharenberg, Andrew M ^e,f   Torgerson, Troy R ^e,f   Rawlings, David J ^e,f   Felsburg, Peter J ^c   Kiem, Hans Peter ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FOAMY VIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CLONE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE REARRANGEMENT; IN VIVO GENE TRANSFER; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; BLOOD CELLS; CELL LINEAGE; DISEASE MODELS, ANIMAL; DOGS; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; SPUMAVIRUS; VIRUS INTEGRATION; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84902133003     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-538926     Document Type: Article

References (42)

1. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet. 2001;357(9271):1863-1869. (Pubitemid 32539123)
2. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004; 22:625-655. (Pubitemid 38680436)
3. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995; 333(7):431-440.
4. Gaspar HB, Howe S, Thrasher AJ. Gene therapy progress and prospects: gene therapy for severe combined immunodeficiency. Gene Ther. 2003; 10(24):1999-2004. (Pubitemid 37407095)
5. White H, Thrasher A, Veys P, Kinnon C, Gaspar HB. Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur J Immunol. 2000;30(3):732-737. (Pubitemid 30216244)
6. Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet. 1990;336(8719):850-854. (Pubitemid 20311334)
7. Wada T, Candotti F. Somatic mosaicism in primary immune deficiencies. Curr Opin Allergy Clin Immunol. 2008;8(6):510-514.
8. Stephan V, Wahn V, Le Deist F, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996;335(21): 1563-1567. (Pubitemid 26384751)
9. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672. (Pubitemid 30241569)
10. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364(9452): 2181-2187. (Pubitemid 40018447)
11. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185-1193. (Pubitemid 34984579)
12. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol. 2010;11(6):457-460.
13. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 [published correction appears in Science. 2003; 302(5645):568]. Science. 2003;302(5644): 415-419. (Pubitemid 37296260)
14. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3): 255-256. (Pubitemid 36077924)
15. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene. 2013;525(2): 170-173.
16. Beard BC, Keyser KA, Trobridge GD, et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther. 2007;18(5):423-434. (Pubitemid 46850134)
17. Trobridge GD, Miller DG, Jacobs MA, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA. 2006; 103(5):1498-1503. (Pubitemid 43191194)
18. Nasimuzzaman M, Persons DA. Cell membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther. 2012;20(6): 1158-1166.
19. Kiem H-P, Allen J, Trobridge G, et al. Foamy-virus-mediated gene transfer to canine repopulating cells. Blood. 2007;109(1):65-70. (Pubitemid 46053045)
20. Trobridge G, Russell DW. Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol. 2004;78(5):2327-2335. (Pubitemid 38228926)
21. Bauer TR Jr, Olson EM, Huo Y, et al. Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter. Gene Ther. 2011;18(6):553-559.
22. Bauer TR Jr, Allen JM, Hai M, et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med. 2008;14(1): 93-97.
23. Trobridge GD, Beard BC, Wu RA, Ironside C, Malik P, Kiem HP. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS ONE. 2012;7(9):e45173.
24. Russell DW, Miller AD. Foamy virus vectors. J Virol. 1996;70(1):217-222. (Pubitemid 126508788)
25. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993;262(5130):117-119.
26. Ponder KP, Melniczek JR, Xu L, et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA. 2002;99(20):13102-13107.
27. Ting-De Ravin SS, Kennedy DR, Naumann N, et al. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. Blood. 2006;107(8):3091-3097.
28. Ponder K.P. Gene therapy goes to the dogs. Blood. 2006;107(8):3018-3019.
29. Kiem H-P, Wu RA, Sun G, von Laer D, Rossi JJ, Trobridge GD. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther. 2010;17(1):37-49.
30. Vernau W, Hartnett BJ, Kennedy DR, et al. T cell repertoire development in XSCID dogs following nonconditioned allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2007;13(9):1005-1015. (Pubitemid 47215563)
31. Adair JE, Beard BC, Trobridge GD, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl. Med. 2012;4(133):133ra57.
32. Berger C, Berger M, Beard BC, Kiem HP, Gooley TA, Riddell SR. Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques. PLoS One. 2013;8(2):e56268.
33. Enssle J, Trobridge GD, Keyser KA, Ironside C, Beard BC, Kiem H-P. Stable marking and transgene expression without progression to monoclonality in canine long-term hematopoietic repopulating cells transduced with lentiviral vectors. Hum Gene Ther. 2010;21(4):397-403.
34. Kabelitz D. gd T-cells: cross-talk between innate and adaptive immunity. Cell Mol Life Sci. 2011; 68(14):2331-2333.
35. Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol. 1999;17:829-874. (Pubitemid 29241141)
36. Johnston JA, Bacon CM, Finbloom DS, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA. 1995;92(19):8705-8709.
37. Sandmaier BM, Schuening FG, Bianco JA, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5(2):125-130.
38. Abraham DR, Rabie H, Cotton MF. Nitazoxanide for severe cryptosporidial diarrhea in human immunodeficiency virus infected children. Pediatr Infect Dis J. 2008;27(11):1040-1041.
39. Pozharisskiǐ KM, Kyshtoobaeva AS, Klimashevskiǐ VF, Chemeris GI. [Morphology of experimental malignant hemangioendothelioma]. Vopr Onkol. 1990;36(3):321-327.
40. Shahiduzzaman M, Daugschies A. Therapy and prevention of cryptosporidiosis in animals. Vet Parasitol. 2012;188(3-4):203-214.
41. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467(7313):318-322.
42. Chan K, Puck JM. Development of populationbased newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005; 115(2):391-398. (Pubitemid 40215109) Diseases Diseases